Paul Sturman joined The Nature’s Bounty Co. as President and Chief Executive Officer in September 2017. He is also a member of the Board of Directors of the Company.
A proven, entrepreneurial and global executive, Paul brings to The Nature’s Bounty Co. 30+ years of success in delivering exceptional results in consumer driven businesses as measured by revenue and income growth, market share, organizational development and shareholder value. Recognized as a disciplined, decisive and authentic leader who builds businesses through insight, clear strategic vision and prioritization of effort, Paul places particular focus upon attracting and inspiring diverse teams to produce superior results. Paul is a risk-taker and change agent with a history of turning businesses around, creating and sustaining conditions for meaningful innovation, and transforming organizations organically and/or through M&A integration.
Paul brings tangible industry experience to his new role having spent six years successfully leading Pfizer’s $3+ billion Consumer Healthcare business (formerly Wyeth), one of the largest over-the-counter (OTC) healthcare products companies in the world. He served as Global President and was responsible for all aspects of the business unit’s operations, including the development and marketing of major household brands such as Advil®, ChapStick®, and Robitussin® as well as vitamin and supplement brands. After integrating the business into Pfizer, Paul led the turnaround of what was a historically declining business to outpace industry consumption growth through organic growth, acquisitions and securing the licensing rights for the prescription to OTC switch of Nexium.
Previously, Paul served as President, North America for Johnson & Johnson Consumer Health Care, where he was responsible for more than 30 brands, including Listerine®, Band-Aid®, Stayfree®, Monistat®, Rogaine®, Neosporin®, and Visine®. He began his marketing career with Warner-Lambert, stewarding brands like Trident sugarless gum, Dentyne Ice, Rolaids antacids, and Halls Cough drops.
A well-regarded executive in the healthcare industry, Paul previously served as Chairman of the Consumer Healthcare Products Association (CHPA) and was a Trustee of the Foundation for Morristown Medical Center, one of “America’s Top 50 Hospitals.” He is currently on the Board of Directors of Tyme Inc., a clinical-stage biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics with low toxicity profiles, and is a member of the Advisory Board for Bucknell University’s Freeman College of Management, his alma mater. Paul is also on the Advisory Board for Johns Hopkins’ Department of Chemical and Biomolecular Engineering.
Paul earned his Bachelor’s degree in Biology and Master’s degree in Business Administration from Bucknell University.